Studies opened since 27 May 2010 and in regulatory process
1 Sep 2010
Study Opened since 27 May 2010
A phase III study of Ienalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/- radiotherapy in patients with advanced cutaneous T-cell lymphoma not previously treated with intravenous chemotherapy
Target Accrual: 100 patients
Study Coordinator:
- Martine Bagot – Hôpital Saint-Louis (AP-HP), Paris
Studies to be opened soon (in regulatory process)
Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with Newly Diagnosed Anaplastic Oligodendroglioma or Anaplastic Mixed Glioma with Chromosomal Co-delections of 1p and 19q.
Target Accrual: 544 patients
Study Coordinators:
- Martin J. Van den Bent – Erasmus University Medical Center, Rotterdam
- Frederic Dhermain – Institut Gustave Roussy, Villejuif
- Wolfgang Wick – Universitaetsklinikum Heidelberg – Kopfklinik, Heidelberg
Randomized trial assessing the significance of Bevacizumab in recurrent grade II and grade III gliomas
Target Accrual: 144 patients
Study Coordinators:
- Martin van den Bent – Erasmus University Medical Center, Rotterdam
- Ahmed Idbaih – CHU Pitié-Salpêtrière, Paris
Clinical and biological characterization of Male Breast Cancer: an international retrospective EORTC, BIG and NABCG intergroup study.
Target Accrual: 1800 patients
Study Coordinator:
- Fatima Cardoso – Institut Jules Bordet – Brussels
Translational research – observational study for identification of new possible prognostic factors and future therapeutic targets in children with acute lymphoblastic leukemia (ALL)
Target Accrual: This trial is a prospective observational – biobanking study.
Study Coordinators:
- Helene Cave, Hôpital Robert Debre (AP-HP), Paris
- Yves Benoit, Universiteit Gent, Gent
Effectiveness of first line treatment with lapatinib and ECF/X in metastatic gastric cancer according to HER2 and EGFR status: a randomized phase II trial
Target Accrual: 228 patients
Study Coordinator:
- Arnaud Roth – Hôpital Cantonal Universitaire De Genève, Genève
Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high risk of locoregional recurrence
Target Accrual: 800 patients for the main study, 150 patients for the pre-study
Study Coordinators:
- Wilfried Budach – Heinrich-Heine Universitaetsklinik Dusseldorf, Duesseldorf
- Johannes Langendijk – University Medical Center Groningen, Groningen
- Carla Van Herpen – Radboud University Nijmegen Medical Center, Nijmegen
A phase IIb/III multicenter study comparing the efficacy of Trabectedin administered as a 3-hour or 24 hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma
Target Accrual: 340 patients
Study Coordinator:
- Binh Bui-Nguyen – Institut Bergonie, Bordeaux
Jennifer Crespo and John Bean
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023